» Articles » PMID: 26349663

High Expression Levels of MiR-21 and MiR-210 Predict Unfavorable Survival in Breast Cancer: a Systemic Review and Meta-analysis

Overview
Specialties Biochemistry
Oncology
Date 2015 Sep 10
PMID 26349663
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Background: MicroRNAs (miRNAs) have been emerging as valuable prognostic biomarkers of breast cancer. We therefore summarized recent research into miRNAs involved in human breast cancer and, further, completed a meta-analysis to predict the role of specific miRNAs in the survival of breast cancer patients.

Methods: Studies were identified by searching PubMed, Embase and Web of Science. Descriptive characteristics for studies were described, and an additional meta-analysis for specific miRNAs was performed. Pooled hazard ratios (HRs) and their corresponding 95% confidence intervals (CIs) were calculated.

Results: A total of 41 articles including 27 types of miRNAs were found regarding prognostic biomarkers for breast cancer survival, of which, micRNA-21 (miR-21) was the most-studied specific miRNA that appeared repeatedly among the selected classifiers. For the studies evaluating miR-21's association with clinical outcomes, the median HR in the studies was 2.32 (interquartile range [IQR] = 1.04-3.40), and the pooled HR suggested that high expression of miR-21 has a negative impact on overall survival (OS; HR = 1.46, 95% CI, 1.25-1.70; p<0.05) and disease/recurrence-free survival in breast cancer (HR = 1.49, 95% CI, 1.17-1.90; p<0.01). We also found that higher expression levels of miR-210 significantly predicted poorer outcome, with median HR in the reported studies of 4.07 (IQR = 1.54-4.43) and a pooled HR of 2.94 (95% CI, 2.08-4.17; p<0.05).

Conclusions: These results indicate that miRNAs show promising associations with prognosis in breast cancer. Moreover, specific miRNAs such as miR-21 and miR-210 can predict poor survival rates in breast cancer patients.

Citing Articles

Circulating Micro-RNAs Predict the Risk of Recurrence in Triple-Negative Breast Cancer.

Kujala J, Tengstrom M, Heikkinen S, Taipale M, Kosma V, Hartikainen J Cells. 2024; 13(22).

PMID: 39594632 PMC: 11593277. DOI: 10.3390/cells13221884.


Clinical importance of serum miRNA levels in breast cancer patients.

Turkoglu F, Calisir A, Ozturk B Discov Oncol. 2024; 15(1):19.

PMID: 38280134 PMC: 10821853. DOI: 10.1007/s12672-024-00871-y.


Sauchinone inhibits breast cancer cell proliferation through regulating microRNA-148a-3p/HER-2 axis.

Hu X, Wang J, Shang P, Wang S, Chen L, Ye C Thorac Cancer. 2023; 14(13):1135-1144.

PMID: 36959089 PMC: 10151132. DOI: 10.1111/1759-7714.14834.


Prognostic and diagnostic values of non-coding RNAs as biomarkers for breast cancer: An umbrella review and pan-cancer analysis.

Bahramy A, Zafari N, Rajabi F, Aghakhani A, Jayedi A, Khaboushan A Front Mol Biosci. 2023; 10:1096524.

PMID: 36726376 PMC: 9885171. DOI: 10.3389/fmolb.2023.1096524.


Potential utility of miRNAs for liquid biopsy in breast cancer.

Liu X, Papukashvili D, Wang Z, Liu Y, Chen X, Li J Front Oncol. 2022; 12:940314.

PMID: 35992785 PMC: 9386533. DOI: 10.3389/fonc.2022.940314.